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Abstract: Modified Mannich reactions of amines, amino acids and a model peptide with 
Ph2PH and CH2O gave bis(diphenylphosphinomethyl)amines (Ph2PCH2)2NR [R= Ph (1), 
CH2CH2OH (2), CH2COOCH2Ph (3), CH2CONHCH2COOCH2Ph (4), CH2COOH (5)] 
and (Ph2PCH2)2NCH2CH2N(CH2PPh2)2 (6). Reaction with [ReBr3(CO)3]
2-
 under mild 
conditions led to ReBr(CO)3{(Ph2PCH2)2NR} [R= Ph (7), CH2CH2OH (8), 
CH2COOCH2Ph (9), CH2CONHCH2COOCH2Ph (10), CH2COOH (11)] and 
[ReBr(CO)3Ph2PCH2)2NCH2]2 (12). All new complexes have been characterized by 
NMR and IR spectroscopy and for 7, 9 and 10, single-crystal X-ray diffraction analyses. 
Stability studies by Electrospray Mass Spectrometry, showed that other than solvolysis, 
the complexes are fairly stable in neutral and acidic methanol. Cytotoxicity testing of 7-
10 and 12 showed that all the complexes are active against specific tumour cell lines. 
 
Introduction 
There is much current interest in the development of radiopharmaceuticals through the 
radiolabeling of monoclonal antibodies with 
186/188
Re.
[1-3]
  Although much emphasis had 
been placed on the development of ligand systems for chelation to the Re(V) oxo core,
[ref]
 
the design of radiopharmaceuticals based on Re(I)-tricarbonyl complexes has gained  
considerable attention recently.
[refs]
  The advantages of this organometallic approach and 
the methodology for generating the [Re(CO)3]
+
 synthon have also been established.
[refs]
   
 It has also been recognised that phosphines, by virtue of their versatile ligating 
capability with transition metals, can play a major role in the design of radiometal-
antibody conjugates.
[5,6,7]
  Work has been done in the area of direct introduction of 
phosphino groups onto peptides and proteins via the Mannich-type reaction of 
hydroxymethyl phosphines and the free amino groups on the protein.
[refs]
  Such 
procedures, however, can potentially alter the structure and hence biological properties of 
the protein.  The use of polyfunctional hydroxymethylphosphines such as P(CH2OH)3, 
for example, can potentially create undesirable cross-links within the protein 
structure,
[refs]
 or link two separate peptides to the same radiometal atom (reducing the 
overall labelling efficiency).  An alternative strategy is the “pre-formed chelate” 
approach, whereby the radiometal is first tightly bonded to a diphosphine chelate system, 
followed by the attachment of the chelate complex unit to the protein via an appropriate 
functional group on the diphosphine (Scheme 1). 
 Bis(diphenylphosphinomethyl)amines are good candidates for the pre-formed 
chelate approach.  They are readily synthesised via the Mannich reaction between 
primary amines and secondary phosphines (with formaldehyde)
[10]
 or 
bis(hydroxymethyl)phosphonium salts
[15]
, and are known to form stable chelate 
complexes with palladium, platinum and rhodium
[16]
.  In principle, any desired functional 
group (for protein conjugation or for increasing water-solubility) can be attached onto the 
nitrogen atom by appropriate choice of the NH2 group-containing starting material 
(Scheme 2).  The fact that the functional group or molecular chain that links the chelate 
unit with the biomolecule is attached to the middle atom of the diphosphine backbone 
means that there should be minimal steric interaction between the radiometal’s 
coordination sphere with the protein.  The relative simplicity of the chelating system is 
also attractive. 
 In the course of our ongoing research on rhenium(I) carbonyl alkoxo complexes,
[4 
and more]
 we have found that the complexes [Re2(-OR)3(CO)6]

 (R = H, Me, Et, Ph), 
[Re2(-OH)(-OPh)2(CO)6]

, [Re2(-OR)2(-dppf)(CO)6] [dppf = 1,1-
bis(diphenylphosphino)ferrocene; R = H, Me, Ph] and fac-[Re(OPh)(2-dppf)(CO)3] 
exhibit potent cytotoxicity against a number of cancer cell lines.
[8b]
  It is of interest, 
therefore, to investigate the anti-tumour activity of bis(diphenylphosphinomethyl)amine 
tricarbonylrhenium(I) complexes as well.  The possibility of having 
bis(diphenylphosphinomethyl)amine tricarbonylrhenium(I)-based radiopharmaceuticals 
serving dual functions as both chemo- and radiotherapeutic agents is appealing. 
 In this paper, we report the synthesis of tricarbonylrhenium(I) complexes of 
representative bis(diphenylphosphinomethyl)amines derived from aniline, glycine, and 
glycylglycine, and the study of their in vitro stability by electrospray mass spectrometry.  
Results of the cytotoxicity screening of these complexes against 18 cancer cell lines are 
also presented. 
 
Experimental Section 
All reactions were performed under pure dry nitrogen using standard Schlenk techniques. 
The solvents were purified and dried by standard methods and distilled under nitrogen 
prior to use. [NEt4]2[Re(CO)3Br3] was prepared by the published procedure
[9]
. 
1
H and 
31
P-
{
1
H} NMR spectra were recorded on a Bruker ACF 300 MHz spectrometer at ca. 300 K 
at operating frequencies of 300.0 and 121.5 MHz, respectively. 
1
H and 
31
P chemical 
shifts are quoted in ppm downfield of tetramethylsilane and external 80% H3PO4, 
respectively. 2-D ROESY NMR analysis was carried out on a Bruker DRX 500 
spectrometer at an operating frequency of 500.23 MHz. IR spectra were taken in a KBr 
disc on a Perkin-Elmer 1600 FT-IR spectrophotometer. Elemental analyses were carried 
out in the Microanalytical Laboratory at the National University of Singapore.  
Cytotoxicity tests were carried out following previously-reported procedures.
[8b]
 
 
Preparation of bis(diphenylphosphinomethyl)amines: 
Bis(diphenylphosphinomethyl)amines (Ph2PCH2)2NR [R=Ph (1), CH2CH2OH (2), 
CH2COOCH2Ph (3), CH2CONHCH2COOCH2Ph (4), CH2COOH (5)] and 
(Ph2PCH2)2NCH2CH2N(CH2PPh2)2 (6) were generally prepared by the published 
procedures
[10]
 with only slight modifications.  
31
P-{
1
H} NMR (CDCl3): 4  -27.3 (s); 5  -
27.0 (s); 6  -28.2 (s). 
 
Preparation of bis(diphenylphosphinomethyl)amine tricarbonylrhenium(I) bromide 
complexes: General Method. – [NEt4]2[Re(CO)3Br3] (144 mg, 0.2 mmol) was dissolved 
in MeOH (30 ml) and an equimolar amount of bis(diphenylphosphinomethyl)amine 
added. The solution was stirred overnight at room temperature, after which the solvent 
was evaporated under reduced pressure and the waxy residue was triturated with Et2O (20 
ml) to form a crystalline solid. After decantation, the product was extracted from the 
[NEt4]Br with THF (30 ml) and precipitated with hexane.  Recrystallization of the solid 
from CH2Cl2/EtOH afforded colorless crystals of the product. 
 
ReBr(CO)3{(Ph2PCH2)2NPh} (7). The bis(diphenylphosphinomethyl)amine 1 (98mg, 
0.2mmol) gave complex 7 as colorless crystals (120mg, 72%). 7 Found for 
C35H29BrNO3P2Re: C 50.21%, H 3.52%, N 1.60%. Calcd: C 50.06%, H 3.48%, N 1.67%. 
1
H NMR (CDCl3):  7.74-7.28 (m, 20H, P-Ph), 7.10 (t, 2H, N-Ph), 6.95 (t, 1H, N-Ph), 
6.26 (d, 2H, N-Ph), 4.75 (m, 2H, H-CH), 4.14 (m, 2H, H-CH). 
31
P-{
1
H} NMR (CDCl3):  
-21.1 (s). IR (cm
-1
, KBr): 2031, 1950, 1901 (CO). 
 
ReBr(CO)3{(Ph2PCH2)2NCH2CH2OH} (8). The bis(diphenylphosphinomethyl)amine 2 
(92mg, 0.2mmol) gave complex 8 as colorless crystals (83mg, 51%). 8 Found for 
C31H29BrNO4P2Re: C 46.05%, H 3.71%, N 1.79%. Calcd: C 46.10%, H 3.62%, N 1.73%. 
1
H NMR (CDCl3):  7.68-7.26 (m, 20H, Ph), 4.31 (m, 2H, H-CH), 3.73 (m, 2H, H-CH), 
3.18 (t, 2H, CH2), 2.71 (s, 2H, CH2). 
31
P-{
1
H} NMR (CDCl3):  -19.6 (s). IR (cm
-1
, KBr): 
2031, 1944, 1899 (CO). 
 
ReBr(CO)3{(Ph2PCH2)2NCH2COOCH2Ph} (9). The 
bis(diphenylphosphinomethyl)amine 3 (110mg, 0.2mmol) gave complex 9 as colorless 
crystals (118mg, 65%). 9 Found for C38H33BrNO5P2Re: C 49.97%, H 3.67%, N 1.60%. 
Calcd: C 50.05%, H 3.65%, N 1.54%. 
1
H NMR (CDCl3):  7.66-7.26 (m, 25H, C6H5), 
5.10 (s, 2H, CH2), 4.63 (m, 2H, CH2), 3.50 (m, 2H, CH2), 3.31 (s, 2H, CH2). 
31
P-{
1
H} 
NMR (CDCl3):  -21.7 (s). IR (cm
-1
, KBr): 2031, 1952, 1896 (CO), 1734 (C=O). 
 
ReBr(CO)3{(Ph2PCH2)2NCH2CONHCH2COOCH2Ph} (10). The 
bis(diphenylphosphinomethyl)amine 4 (124mg, 0.2mmol) gave complex 10 as colorless 
crystals (134mg, 69%). 10 Found for C40H36BrN2O6P2Re: C 49.65%, H 3.81%, N 2.92%. 
Calcd: C 49.59%, H 3.75%, N 2.89%. 
1
H NMR (CDCl3): 7.44-7.25 (m, 25H, Ph), 5.50 
(m, 1H, NH), 5.13 (m, 2H, O-CH2-Ph), 4.37-4.36 (m, 2H, N-HCH-P), 3.47-3.37 (m, 2H, 
N-HCH-P), 3.33-3.30 (m, 4H, N-CH2-C). 
31
P-{
1
H} NMR (CDCl3):  -18.1 (s). IR (cm
-1
, 
KBr): 2032, 1954, 1904 (CO), 1735, 1673 (C=O). 
 
ReBr(CO)3{(Ph2PCH2)2NCH2COOH} (11). The bis(diphenylphosphinomethyl)amine 5 
(110mg, 0.2mmol) gave complex 11 as colorless crystals (87mg, 53%). 11 Found for 
C31H27BrNO5P2Re: C 45.51%, H 3.27%, N 1.73%.  Calcd: C 45.32%, H 3.31%, N 
1.70%. 
1
H NMR (CDCl3):  7.71-7.29 (m, 20H, Ph), 4.62 (m, 2H, H-CH), 3.47 (m, 2H, 
H-CH), 3.32 (s, 2H, N-CH2-C). 
31
P-{
1
H} NMR (CDCl3):  -21.7 (s). IR (cm
-1
, KBr ): 
2029, 1948, 1909 (CO), 1718 (C=O). 
 
[ReBr(CO)3(Ph2PCH2)2NCH2]2 (12). [Re(CO)3Br3][NEt4]2 (144 mg,  0.2 mmol) was 
dissolved in MeOH (30 ml) and the bis(diphenylphosphinomethyl)amine 6 (85mg, 
0.1mmol) added. The solution was stirred overnight at room temperature, the solvent 
evaporated under reduced pressure giving a waxy residue. The residue was separated, 
washed with THF and then with EtOH/H2O, giving 12 as a colorless solid (97mg, 63%). 
12 Found for C60H52Br2N2O6P4Re2: C 46.51%, H 3.31%, N 1.76%. Calcd: C 46.40%, H 
3.37%, N 1.80%. 
31
P-{
1
H} NMR (CDCl3):  -20.7 (s). IR (cm
-1
, KBr): 2035, 1953, 1945, 
1925, 1907 (CO). 
 
Electrospray mass spectrometry. All ESMS spectra were recorded in positive-ion mode 
using a VG Platform II instrument employing nitrogen as both the drying and nebulizing 
gas.  The spectra were typically obtained with an average of ten to twelve scans. A range 
of cone voltages, from 20-100 V were typically applied on each sample to investigate the 
fragmentation behavior. The analyte solution (Approx 0.1 mM) was delivered to the mass 
spectrometer source using a Spectra System P1000 HPLC pump, at a flow rate of 0.01 ml 
min
-1
.  Spectra were recorded in neutral, acidic and basic MeOH solutions, as well as in 
MeCN-H2O solutions.  Acidic solutions were prepared by dilution of 5 drops of 50% 
formic acid to 2mL with methanol. Two drops of this solution were added to the rhenium 
complex solutions, and the mixture allowed to stand for several weeks. Basic solutions 
were prepared by adding three drops NH3 solution (2 M) to the rhenium complex 
solution, and the mixture allowed to age over one month. Assignment of major ions was 
aided by a comparison of the experimental and calculated isotope distribution patterns, 
the latter obtained using the Isotope program
[11]
. 
 
X-ray Crystallography.   
Colorless crystals of 7 suitable for X- ray diffraction analysis were obtained from a 
CH2Cl2/CHCl3/C2H5OH solution at –20
o
C and colorless crystals of 9 and 10 were 
obtained from a CH2Cl2/C2H5OH solution at –20
o
C.  Data collection was carried out on a 
Siemens SMART CCD diffractometer using Mo-K radiation ( 0.71073 Å).  The data 
were corrected for absorption effects using the SADABS program.
12aa
  Crystal and 
refinement data are summarised in Table 1. 
 The structures of the three complexes were solved by direct methods and 
difference Fourier maps.  Full-matrix least-squares refinements (on F
2
) were carried out 
with anisotropic thermal parameters for all non-hydrogen atoms, using all of the unique 
data.  All hydrogen atoms were introduced in calculated positions and refined using the 
riding model.  Computations were carried out using the SHELXTL software package.
[12]
  
Crystallographic data for the structural analyses have been deposited with the Cambridge 
Crystallographic Data Centre, CCDC No. xxxxx for 7, xxxxx for 9, xxxxx for 10.  
Selected geometric parameters of the complexes are given in Table 2. 
 
Results and Discussion 
Syntheses 
The Mannich reactions of aniline, ethanolamine H2NCH2COOCH2C6H5, 
H2NCH2CONHCH2COOCH2C6H5, H2NCH2COOH and ethylene diamine gave 
bis(diphenylphosphinomethyl)amines 1 - 6, respectively. Reactions of  
[NEt4]2[Re(CO)3Br3] and these bis(diphenylphosphinomethyl)amines give 7 - 12, 
respectively (Scheme 1). Complex 7 - 10 are soluble in CH2Cl2, CHCl3 and poorly 
soluble in H2O, MeOH, EtOH. Complex 11 has increased solubility in H2O due to its 
carboxylic group, which can potentially be functionalized. Unexpectedly complex 12 is 
virtually insoluble in all these solvents.  
 
Crystal structures 
In order to confirm the formation and geometry of the rhenium diphosphine complexes, 
X-ray structure determinations were carried out on 7, 9 and 10.  Rhenium preferentially 
bonds to the phosphorus atoms of these bis(diphenylphosphinomethyl)amines as 
expected.  The nitrogen atoms are uncoordinated and the six-membered chelate rings 
adopt chair conformations with the nitrogen and rhenium atoms out of the plane formed 
by the C2P2 unit.  This is unlike the reported palladium, platinum and rhodium complexes 
of bis(diphenylphosphinomethyl)amines, in which the chelate rings adopt a flattened 
chair conformation with only the nitrogen atom substantially out of the plane formed by 
the C2P2M (M = Pd, Pt or Rh)
[16]
 unit.  The nitrogen atoms of compounds 7, 9 and 10 are 
progressively more pyramidal [average C-N-C angles: 116.0(7) for 7, 112.7(3) for 9, 
and 109.6(2) for 10]; this is most likely a reflection of the decreasing steric hindrance at 
the nitrogen atom.  The carbonyl groups are in the expected facial arrangement within the 
distorted octahedral coordination sphere of each of compounds 7, 9 and 10.  The Re-Br, 
Re-CO and Re-P distances found for these structures are typical for analogous rhenium(I) 
tricarbonyl complexes
[18]
. 
 
NMR Spectroscopy 
The 
31
P-{
1
H} NMR spectrum of each rhenium complex consists of a single sharp 
resonance, indicating the formation of a single isomer with a plane of symmetry. The 
1
H 
NMR spectra show a characteristic pattern for the methylene protons of the chelate ring.  
There are two distinct environments for the four protons, due both to the equatorial/axial 
distinction in the chair conformation, and to the position of the bromide ligand.  The 
1
H-
1
H ROESY spectrum of complex 7 is shown in Fig. 4 as a representative spectrum.  The 
signal at 4.14 ppm is assigned to the equatorial protons because these protons are nearer 
to the ortho protons of the N-bonded phenyl ring (Fig. 1), and hence are expected to have 
stronger interaction with the latter (cross-peak B is stronger than cross-peak C). 
 
Electrospray (ES) mass spectrometric characterisation 
Positive-ion ES spectra of the rhenium bis(diphenylphosphinomethyl)amine complexes 7 
– 10 and 12 were recorded in both methanol and acetonitrile-water solutions; ions 
observed in methanol solution are given in Table 3.   Generally, spectra recorded in 
methanol were of better quality, probably due to improved solubility in this solvent, 
however spectra for 12 were unable to be obtained.  At cone voltages of 50 - 60 V 
complexes 7, 8, 9 and 10 give both [M + H]
+
 and [M – Br]+ ions, with the relative 
intensity of the former decreasing with increasing cone voltage.  The presence or absence 
of Br in an ion can be readily ascertained from the isotope pattern of the ion, due to the 
distinctive isotopic signature of bromine. At low cone voltages (e.g. 20 V) spectra are 
dominated by the [M + H]
+
 ions (e.g. for 8 at m/z 808). For complex 7, protonation can 
only be at the nitrogen atom, since the CO ligands are not expected to show any basicity, 
but for 8, 9 and 10, there are additional oxygen atoms which are also available for 
protonation. Aggregate ions of the type [2M + H]
+
 were observed in some cases. 
Complex 10 showed a strong [2M + H]
+
 ion (m/z 1940), presumably due to the ready 
ability of this species to engage in hydrogen bonding.  Further increasing the cone 
voltage  (to 80 V or higher) results in loss of CO ligands, e.g for 9, where ions [M – Br – 
CO]
+
 (m/z 804) and [M – Br – 2CO]+ (m/z 776) ions were observed at 100 V. 
In some cases several drops of pyridine were added to the analyte solutions, both 
to increase the solubility of the complexes (which in some cases were of low solubility) 
and to investigate whether the neutral pyridine ligand could replace the bromide ligand, 
leading to charged [M – Br + pyridine]+ ions, as has been observed for a wide range of 
other transition metal halide complexes
[19]
. However, no pyridine-containing ions were 
observed.  Finally, the negative-ion spectrum of complex 8 was recorded, but no ions 
(expected to be formed by deprotonation of the OH group) were observed. 
 
Stability studies 
The stability of the rhenium-phosphine complexes, in neutral, acidic and basic methanol 
solutions has also been qualitatively surveyed by ES mass spectrometry, by recording 
spectra of solutions aged for several weeks.  In neutral solutions, spectra of complexes 7, 
8, and 9 were generally similar to those of fresh solutions, giving [M + H]
+
 and [M – Br]+ 
ions.  Comparison of the aged solution of 8 with a fresh solution indicated that the aged 
solution had a higher intensity [M – Br]+ ion, together with additional low intensity ions 
[M – Br + NH3]
+
 and [M – Br + MeOH]+.  For complex 10, the expected [M + H]+ and 
[M – Br]+ ions were observed, together with a weak ion at m/z 879, assigned to 
[ReBr(CO)3{(Ph2PCH2)2NCH2C(O)NHCH2CO2H} + H]
+
, formed by hydrolysis of the 
terminal benzyl group in 10. These observations suggest that the complexes are generally 
stable in neutral methanol, and that ES mass spectrometry can be used to identify 
degradation products. 
In aged acidic solutions (prepared by addition of a small quantity of formic acid to 
the Re complex solutions), complexes 7, 8 and 9 again yielded similar spectra to the 
neutral solutions, indicating that the complexes are quite stable in dilute acid solutions.   
The ion [PhN{CH2P(O)Ph2}2 + H]
+
 (m/z 522) was observed for 7, which was not seen in 
fresh solutions, nor in the aged neutral solution.  For complex 10 considerable 
decomposition appeared to occur, with one ion at m/z 760 assigned to 
[Re(CO)3(MeOH){(Ph2PCH2)2NCH2CO2H}]
+
 and the corresponding unsolvated ion at 
m/z 729.  This seems to suggest that the C(O)NH linkage of 10 is susceptible to acid 
hydrolysis but the C(O)O linkage of 9 is less so.  This observation may have implications 
on the choice of linker chains between the metal complex moiety and the antibody in the 
radiopharmaceutical conjugate.  Ideally, the linker chain must be sufficiently stable to 
allow the conjugate to survive the journey to the target tumour site, but must be 
metabolizable to facilitate the clearance of radioactivity from non-target tissue.
[17]
 
In aged basic solutions (formed by addition of dilute NH3 solution) reactivity was 
much greater, and more hydrolysis was observed.  For 7, the diphosphine dioxide ion at 
m/z 522 was more intense, a weak [M + H]
+
 ion was seen, together with major ions [M – 
Br + NH3]
+
 and [M – Br + MeOH]+; complex 8 behaved similarly.  For 9 considerable 
solvolylsis occurred, with the base peak at m/z 759 assigned to 
[Re(CO)3(MeOH){Ph2PCH2)2CH2CO2H}]
+
, plus other unidentified ions.  This ion is 
formed by loss of the bromide ion (and coordination of methanol) together with 
solvolysis of the ester linkage.  Solvolysis of 10 appeared to be even more severe, though 
interestingly, the ions formed under acidic conditions were not seen. 
These preliminary studies suggest that the rhenium-
bis(diphenylphosphinomethyl)amine complexes possess significant stability in neutral 
and mildly acidic solutions, but substantial degradation occurs in basic solution.  It must 
be emphasised, however, that the diphosphine-rhenium chelate unit remains largely intact 
in all the above studies, i.e. any degradation observed does not cleave the diphosphine 
from the rhenium atom.  This is significant because one of the most important criteria for 
choosing a ligand system for the conjugation of radionuclides to antibodies for 
radioimmunotherapy is the stability of the conjugate.  The solvolysis in basic medium 
may also represent a possible pathway for the interaction of the [ReBr(CO)3] moiety with 
blood proteins. 
 
Cytotoxicity 
Complexes 7-10 and 12 generally showed potent cytotoxicity in the suspended murine 
and human leukemias and lymphoma, as well as the HeLa suspended uterine carcinoma 
cells (Table 4).  The compounds were however much more selective in inhibiting the 
growth of tumours derived from human solid cancers. 
The pattern of cytotoxic activity shown by complexes 7-10 and 12 shows some 
similarities to that of the rhenium alkoxo complexes [Re2(-OR)3(CO)6]

 (R = H, Me, Et, 
Ph), [Re2(-OH)(-OPh)2(CO)6]

, [Re2(-OR)2(-dppf)(CO)6] [dppf = 1,1-
bis(diphenylphosphino)ferrocene; R = H, Me, Ph] and fac-[Re(OPh)(2-dppf)(CO)3] 
[8b]
.  
For example, all of these rhenium complexes show activity against L1210 mouse 
leukemia, P388 mouse lymphocytic leukemia, HuT-78 Lymphoma and HeLa-S
3
 susp 
uterine cells, and all are inactive against KB nasopharynx cells.  However, complexes 7-
10 and 12 show much higher activity against MCF-7 breast cancer cells than the rhenium 
alkoxo complexes. 
It is noteworthy that compounds 7-10 and 12 show no activity against normal 
human cells.  This is an important property for any chemotherapeutic agent since harmful 
side-effects of the treatment will be minimised. 
 
Conclusion 
Bis(diphenylphosphinomethyl)amines are excellent chelating ligands to 
tricarbonylrhenium(I) fragments. Complex 11 has a free carboxyl group offering a 
potentially reactive site for functionalization and coupling to antibodies.  Deprotection of 
complexes 9 and 10 by removal of the benzyl group by hydrogenation would also yield 
free carboxyl groups for protein conjugation.  ESMS studies show that the rhenium-
phosphine chelate unit is very stable, especially in neutral solution (similar pH to blood 
serum).  These bis(diphenylphosphinomethyl)amine rhenium(I) complexes thus provide 
an ideal model for the labeling of antibodies or other amine-containing biomolecules with 
radioactive tricarbonylrhenium(I) fragments for radioimmunotherapy.  Complexes 7-10 
and 12 also show cytotoxic activity against several murine and human cancer cell lines, 
suggesting that bis(diphenylphosphinomethyl)amine rhenium(I) complexes with 
186
Re or 
188
Re radionuclides can potentially have dual functions, as both chemo- and 
radiotherapeutic agents, in cancer therapy. 
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Table 1. Crystallographic Data 
 7·CHCl3 9 10 
formula C36H30BrC13NO3P2Re C38H33BrNO5P2Re C40H36BrN2O6P2Re 
fw 959.01 911.70 968.76 
space group P-1 Pbca P-1 
cryst syst Triclinic Orthorhombic Triclinic 
a (Å) 11.6694(5) 16.4076(3) 9.9690(1) 
b (Å) 12.4671(6) 17.3407(4) 12.4920(2) 
c (Å) 14.8036(7) 25.0776(5) 16.1088(2) 
α (o) 113.358(1) 90 102.511(1) 
β (o) 98.992(1) 90 96.301(1) 
γ (o) 105.582(1) 90 94.926(1) 
V (Å
3
) 1818.5(2) 7135.1(3) 1934.14(4) 
Z 2 8 2 
Dcalcd (Mg m
-3
) 1.751 1.697 1.663 
F(000) 936 3584 956 
μ(Mo Kα) (mm-1) 4.785 4.660 4.305 
temp (K) 293(2) 223(2) 223(2) 
no. of reflns collected 9064 42627 12688 
no. of unique reflns 5965 9017 9000 
goodness-of-fit on F
2 
1.035 1.068 1.034 
R1
a 
0.0511 0.0332 0.0288 
wR2
b 
0.1111 0.0547 0.0643 
a
 R1 = Σ||Fo| - |Fc||/Σ|Fo|. 
b
 wR2 = [Σ[w(Fo
2
 - Fc
2
)
2]/Σ[w(Fo
2
)
2
]]
1/2
. 
 
Table 2. Selected bond lengths (Å) and bond angles (
o
) for 7, 9 and 10 with estimated 
standard deviations in parentheses 
 
 7 9 10 
 
Re(1)-C(1) 1.900(11) 1.893(3) 1.898(4) 
Re(1)-C(2) 1.941(11) 1.964(4) 1.951(4) 
Re(1)-C(3) 1.942(12) 1.969(3) 1.949(4) 
Re(1)-P(2) 2.461(2) 2.4669(8) 2.4561(8) 
Re(1)-P(1) 2.468(2) 2.4848(8) 2.4690(9) 
Re(1)-Br(1) 2.6460(10) 2.6604(4) 2.6537(4) 
P(1)-C(4) 1.853(8) 1.853(3) 1.856(3) 
P(2)-C(5) 1.852(8) 1.851(3) 1.849(3) 
N(1)-C(4) 1.464(10) 1.474(4) 1.478(4) 
N(1)-C(5) 1.452(10) 1.476(4) 1.471(4) 
N(1)-C(1E) 1.416(10)   
N(1)-C(6)  1.462(4) 1.485(4) 
 
C(1)-Re(1)-C(2) 89.5(4) 88.40(14) 89.25(16) 
C(1)-Re(1)-C(3) 90.3(4) 89.95(14) 88.98(15) 
C(2)-Re(1)-C(3) 89.3(4) 89.86(15) 89.18(18) 
C(1)-Re(1)-P(2) 95.3(3) 94.56(10) 93.68(10) 
C(2)-Re(1)-P(2) 91.2(3) 90. 19(11) 91.03(13) 
C(3)-Re(1)-P(2) 174.4(3) 175.49(11) 177.33(11) 
C(l)-Re(1)-P(1) 95.1(3) 97.31(10) 96.20(12) 
C(2)-Re(1)-P(1) 175.3(3) 173.14(11) 174.44(11) 
C(3)-Re(1)-P(1) 91.4(3) 93.92(10) 92.04(13) 
P(2)-Re(1)-P(1) 87.66(7) 85.60(3) 87.50(3) 
C(1)-Re(1)-Br(1) 175.7(3) 176.16(10) 177.74(11) 
C(2)-Re(1)-Br(1) 86.6(3) 87.76(11) 91.29(11) 
C(3)-Re(1)-Br(1) 91.6(3) 89.97(11) 88.83(l1) 
P(2)-Re(1)-Br(1) 82.83(6) 85.52(2) 88.51(2) 
P(1)-Re(1)-Br(1) 98.73(6) 86.52(2) 83.31(2) 
C(4)-P(1)-Re(1) 115.2(3)  114.06(11) 114.41(11) 
C(5)-P(2)-Re(l) 112.6(3) 113.35(11) 116.19(11) 
C(1E)-N(1)-C(5) 116.0(7) 
C(1E)-N(1)-C(4) 118.8(7)  
C(6)-N(1)-C(4)  111.2(3) 109.0(2) 
C(6)-N(1)-C(5)  111.8(2) 107.4(2) 
C(5)-N(1)-C(4) 113.3(7) 115.2(3) 112.3(2) 
N(1)-C(4)-P(1) 112.8(5) 113.9(2) 112.4(2) 
N(1)-C(5)-P(2) 112.5(5)  113.7(2) 117.6(2) 
___________________________________________________________________ 
Table 3. ESMS data for the rhenium bis(diphenylphosphinomethyl)amine complexes in 
methanol 
 
Complex Cone Voltage Fragment assignment [m/z, relative intensity (%)] 
 
7  20V  [M+H]
+
 (m/z 840, 100%), [M-Br]
+
 (m/z 760, 55%) 
  50V  [M+H]
+
 (m/z 840, 52%), [M-Br]
+
 (m/z 760, 100%) 
8 20V [M+H]
+
 (m/z 808, 100%), [M-Br]
+
 (m/z 728, 5%), [2M+H]
+
 
(m/z 1615/1617, 5%) 
 50V [M+H]
+
 (m/z 808, 100%), [M-Br]
+
 (m/z 728, 53%), 
[2M+H]
+
 (m/z 1615/1617, 3%) 
9 20V [M+H]
+
 (m/z 912, 100%), [M-Br]
+
 (m/z 832, 12%), 
[2M+H]
+
 (m/z 1823/1825, 10%) 
 50V  [M+H]
+
 (m/z 912, 100%), [M-Br]
+
 (m/z 832, 90%) 
10 20V [M+H]
+
 (m/z 969, 100%), [M-Br]
+
 (m/z 889, 5%), [2M+H]
+
 
(m/z 1937/1939, 10%) 
 50V [M+H]
+
 (m/z 969, 100%), [M-Br]
+
 (m/z 889, 73%), 
[2M+H]
+
 (m/z 1615/1617, 18%) 
12 50V [M+H]
+
 (m/z 1554), [M-Br]
+
 (m/z 1473), plus several 
unidentified ions 
 
________________________________________________________________________ 
 
 
Table 4. Cytotoxicity expressed as ED50 values (µg ml
-1
)
a
 
 
Tumor Cell Line 7 8 9 10 12 
 
L1210 mouse Leukemia 2.36 1.72  1.92  2.80  2.90 
P388 mouse lymphocytic 2.72 2.91  2.30  3.61  2.02  
Leukemia 
HL-60 human Leukemia 3.42 3.33  2.14  3.37  2.05 
Tmolt3 T cell Leukemia 3.27 4.70  5.17  3.01  3.06  
T molt4 T cell Leukemia 4.52 4.36  4.32  3.64  6.16 
HuT-78 Lymphoma 2.60 2.96  2.55  3.53  2.70 
THP-1 Acute Monocytic 2.10 3.28  3.30  5.21  3.87 
Leukemia 
HeLa-S
3
 susp Uterine 2.69 2.32  2.68  2.85  1.45 
KB Nasopharynx 6.88 4.88  4.34  6.45  5.49 
Lung 549 8.02 4.02  8.51  3.24  6.82 
Liver Hepe-2 4.76 5.07  4.02  4.49  3.74 
Ovary 1-A9 7.71 3.39  8.92  3.72  7.39 
Breast MCF-7 3.52 2.01  2.37  2.42  1.53 
Glioma UM 86 8.99 6.49  9.05  6.67  7.78 
Ileum HCT-8 5.45 10.69  3.95  4.55  5.65 
Prostate PL 3.90 7.30  5.06  8.61  4.95 
Osteosarcoma HSO 4.59 5.32  5.86  7.72  5.00 
Melanoma SK2 6.11 4.18  3.45  13.3  2.87 
Normal RMPI 1788 6.78 7.02  7.60  6.86  9.31 
____________________________________________________________________ 
 
a
  ED50 values refer to the concentration of the compound inhibiting 50% of cell growth. 
A value of less than 4 µg ml
1
 is required for significant activity for inhibition of cell 
growth. 
Figure 1. Crystal structure of [ReBr(CO)3{(Ph2PCH2)2NPh}] 7 with 40% probability 
thermal ellipsoids.  Hydrogen atoms on phenyl rings are omitted for clarity. 
 
Figure 2. Crystal structure of [ReBr(CO)3{(Ph2PCH2)2NCH2COOCH2Ph}] 9 with 50% 
probability thermal ellipsoids.  Hydrogen atoms are omitted for clarity. 
 
Figure 3. Crystal structure of [ReBr(CO)3{(Ph2PCH2)2NCH2CONHCH2COOCH2Ph}] 10 
with 50% probability thermal ellipsoids.  Hydrogen atoms are omitted for clarity. 
 
Figure 4. Two-dimensional 
1
H ROESY NMR spectrum of complex 7 in CDCl3 at 300.0 
K.  Cross-peaks: A, equatorial-CH2 ··· axial-CH2; B, equatorial-CH2 ··· p-N-C6H5; C, 
axial-CH2 ··· o-N-C6H5. 
 
 
  
